Compare KRMD & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | IPHA |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.5M | 165.3M |
| IPO Year | 2019 | 2014 |
| Metric | KRMD | IPHA |
|---|---|---|
| Price | $3.16 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $6.50 | $5.75 |
| AVG Volume (30 Days) | ★ 221.0K | 52.7K |
| Earning Date | 05-06-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,127,366.00 | N/A |
| Revenue This Year | $20.32 | $180.36 |
| Revenue Next Year | $17.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.23 | N/A |
| 52 Week Low | $3.12 | $1.18 |
| 52 Week High | $6.61 | $2.71 |
| Indicator | KRMD | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 29.99 | 41.28 |
| Support Level | N/A | $1.67 |
| Resistance Level | $3.43 | $1.95 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 11.11 | 0.00 |
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.